Citigroup
ABMD

Citigroup’s Abiomed Inc ABMD Stock Holding History

Citigroup’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-40,942
Closed -$10.1M – 6126
2022
Q3 		$10.1M Buy
40,942
+2,165
+6% +$585K 0.01% 1141
2022
Q2 		$9.6M Buy
38,777
+8,884
+30% +$2.4M 0.01% 1173
2022
Q1 		$9.9M Sell
29,893
-5,327
-15% -$1.64M 0.01% 1305
2021
Q4 		$12.6M Buy
35,220
+4,580
+15% +$1.55M 0.01% 1256
2021
Q3 		$9.97M Sell
30,640
-13,745
-31% -$4.66M 0.01% 1414
2021
Q2 		$13.9M Buy
44,385
+5,881
+15% +$1.8M 0.01% 1217
2021
Q1 		$12.3M Sell
38,504
-6,304
-14% -$2.02M 0.01% 1250
2020
Q4 		$14.5M Sell
44,808
-740
-2% -$205K 0.01% 1268
2020
Q3 		$12.6M Buy
45,548
+14,979
+49% +$4.32M 0.01% 1199
2020
Q2 		$7.38M Sell
30,569
-11,854
-28% -$2.38M 0.01% 1549
2020
Q1 		$6.16M Buy
42,423
+7,152
+20% +$1.19M 0.01% 1498
2019
Q4 		$6.02M Sell
35,271
-11,632
-25% -$2.16M ﹤0.01% 1882
2019
Q3 		$8.34M Buy
46,903
+20,103
+75% +$4.35M 0.01% 1531
2019
Q2 		$6.98M Sell
26,800
-14,739
-35% -$3.91M 0.01% 1682
2019
Q1 		$11.9M Buy
41,539
+10,364
+33% +$3.44M 0.01% 1158
2018
Q4 		$10.1M Buy
31,175
+6,325
+25% +$2.2M 0.01% 1246
2018
Q3 		$11.2M Buy
24,850
+17,582
+242% +$6.93M 0.01% 1210
2018
Q2 		$2.97M Buy
7,268
+4,962
+215% +$1.8M ﹤0.01% 2330
2018
Q1 		$671K Sell
2,306
-29,937
-93% -$7.59M ﹤0.01% 3680
2017
Q4 		$6.04M Buy
32,243
+30,900
+2,301% +$5.77M ﹤0.01% 1657
2017
Q3 		$226K Buy
1,343
+347
+35% +$52.5K ﹤0.01% 4888
2017
Q2 		$143K Sell
996
-1,705
-63% -$229K ﹤0.01% 5067
2017
Q1 		$338K Buy
2,701
+493
+22% +$57.1K ﹤0.01% 4199
2016
Q4 		$249K Sell
2,208
-6,913
-76% -$801K ﹤0.01% 5097
2016
Q3 		$1.17M Buy
9,121
+7,937
+670% +$951K ﹤0.01% 3051
2016
Q2 		$129K Sell
1,184
-29,125
-96% -$2.9M ﹤0.01% 4871
2016
Q1 		$2.87M Buy
30,309
+26,994
+814% +$2.28M ﹤0.01% 2106
2015
Q4 		$299K Sell
3,315
-3,715
-53% -$315K ﹤0.01% 4357
2015
Q3 		$652K Sell
7,030
-249
-3% -$21.9K ﹤0.01% 3488
2015
Q2 		$478K Sell
7,279
-693
-9% -$46K ﹤0.01% 3744
2015
Q1 		$571K Buy
7,972
+1,559
+24% +$84.6K ﹤0.01% 3613
2014
Q4 		$244K Sell
6,413
-5,627
-47% -$177K ﹤0.01% 4522
2014
Q3 		$299K Buy
12,040
+1,151
+11% +$29.2K ﹤0.01% 3933
2014
Q2 		$274K Buy
10,889
+444
+4% +$10.3K ﹤0.01% 3870
2014
Q1 		$272K Buy
10,445
+254
+2% +$7.03K ﹤0.01% 4038
2013
Q4 		$273K Sell
10,191
-37,418
-79% -$925K ﹤0.01% 4384
2013
Q3 		$908K Buy
47,609
+37,406
+367% +$855K ﹤0.01% 2972
2013
Q2 		$220K Buy
+10,203
New +$205K ﹤0.01% 4199

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citigroup's ABMD Position: Q4 2022 in Review

Citigroup sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 40,942 shares — an estimated $10.1M sold.

Citigroup first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $14.5M in Q4 2020. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Citigroup reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 40,942 Abiomed Inc shares in Q4 2022, an estimated $10.1M.
  • Citigroup first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Citigroup's Abiomed Inc position peaked at $14.5M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.